The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 10, 2023

Filed:

Oct. 11, 2019
Applicant:

The Johns Hopkins University, Baltimore, MD (US);

Inventors:

Alfredo Quinones-Hinojosa, Bel Air, MD (US);

Jordan Green, Nottingham, MD (US);

Assignee:

The Johns Hopkins University, Baltimore, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/28 (2015.01); A61K 31/711 (2006.01); A61K 35/761 (2015.01); A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); A61K 38/45 (2006.01); A61K 45/06 (2006.01); A61K 9/51 (2006.01); C12N 5/0775 (2010.01);
U.S. Cl.
CPC ...
A61K 35/28 (2013.01); A61K 9/5146 (2013.01); A61K 9/5153 (2013.01); A61K 9/5176 (2013.01); A61K 31/711 (2013.01); A61K 35/761 (2013.01); A61K 38/1709 (2013.01); A61K 38/1875 (2013.01); A61K 38/20 (2013.01); A61K 38/208 (2013.01); A61K 38/2013 (2013.01); A61K 38/212 (2013.01); A61K 38/215 (2013.01); A61K 38/45 (2013.01); A61K 45/06 (2013.01); C12N 5/0667 (2013.01); C12Y 207/01021 (2013.01); C12N 2510/02 (2013.01);
Abstract

The presently disclosed subject matter provides compositions, methods, and kits for transfecting adipose-derived mesenchymal stem cells (AMSCs) in freshly extracted adipose tissue using nanoparticles comprising biodegradable polymers self-assembled with nucleic acid molecules. The presently disclosed subject matter also provides methods for treating a neurological disease in a patient in need thereof, the method comprising administering the AMSCs transfected with the nucleic acid molecules to the patient, wherein the nucleic acid molecules encode one or more bioactive molecules functional in the treatment of a neurological disease, particularly wherein the neurological disease is a brain tumor.


Find Patent Forward Citations

Loading…